Which Anthropometric Measurement is better for Predicting Survival of Patients with Cancer Cachexia?

Yi-Zhong Ge 1,2,3,4*, Guo-Tian Ruan 2,3,4*, Kang-Ping Zhang 2,3,4*, Meng Tang 2,3,4, Qi Zhang 2,3,4, Xi Zhang 2,3,4, Meng-Meng Song 2,3,4, Xiao-Wei Zhang 2,3,4, Ming Yang 2,3,4, Xian Shen 1, Hong-Xia Xu 5, Chun-Hua Song 6, Chang Wang 7, Han-Ping Shi, MD, PhD 1,2,3,4#

1The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, 325000, China;

2Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China;

3Department of Oncology, Capital Medical University, Beijing, 100038, China;

4Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing, 100038, China;

5Department of Clinical Nutrition, Daping Hospital, Army Medical University, Chongqing 400042, China;

6Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, China;

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI

10.1017/S0007114521002853

The British Journal of Nutrition is published by Cambridge University Press on behalf of The Nutrition Society
Accepted manuscript

7Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021 China;

*Yi-Zhong Ge, Guo-Tian Ruan, and Kang-Ping Zhang contributed equally to this work and therefore share first authorship.

#Correspondence to: Dr Han-Ping Shi, Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China; E-mail: shihp@ccmu.edu.cn.

This work was supported by the National Key Research and Development Program (2017YFC1309200).

Short Title: Anthropometric Measurement and Cancer Cachexia

The data described in the manuscript, code book, and analytic code will be made available upon request pending application and approval.
Abstract

No relevant studies have yet been conducted to explore which measurement can best predict the survival time of patients with cancer cachexia. This study aimed to identify an anthropometric measurement that could predict the 1-year survival of patients with cancer cachexia. We conducted a nested case-control study using data from a multicenter clinical investigation of cancer from 2013 to 2020. Cachexia was defined using the Fearon criteria. A total of 262 patients who survived less than 1 year and 262 patients who survived more than 1 year were included in this study. Six candidate variables were selected based on clinical experience and previous studies. Five variables; body mass index, mid-arm circumference, mid-arm muscle circumference, calf circumference, and triceps skin fold (TSF), were selected for inclusion in the multivariable model. In the conditional logistic regression analysis, TSF (p=0.014) was identified as a significant independent protective factor. A similar result was observed in all patients with cancer cachexia (n=3084). In addition, a significantly stronger positive association between TSF and the 1-year survival of patients with cancer cachexia was observed in participants aged >65 years (OR: 0.94; 95% CI: 0.89, 0.99) than in those aged ≤65 years (OR: 0.96; 95% CI: 0.93, 0.99; P-interaction =0.013) and in participants with no chronic disease (OR: 0.92; 95% CI: 0.87, 0.97) than in those with chronic disease (OR: 0.97; 95% CI: 0.94,1.00; P-interaction =0.049). According to this study, TSF might be a good anthropometric measurement for predicting 1-year survival in patients with cancer cachexia.

Keywords: triceps skin fold, survival, cancer cachexia, anthropometric measurement, malnutrition
Introduction

Cancer cachexia is characterized by unintentional body weight loss, especially loss of skeletal muscle mass, and a loss of homeostatic control of both energy and protein balance, which negatively affects the quality of life and survival of patients with cancer (1). The progression of cancer cachexia is based on the patients’ response to tumor progression, including parameters such as the activation of inflammation and energetic inefficiency in the mitochondria (2). In addition to the loss of skeletal muscle mass, cancer cachexia is now considered to be a systemic paraneoplastic syndrome that affects and compromises a variety of tissues, including adipose tissue, heart, blood, liver, and additional tissues (3). In progressive cancer cachexia, body fat loss, caused by the hydrolysis of triglyceride into free fatty acids and glycerol, often precedes muscle loss (4). Recent studies have revealed that brown adipose tissue metabolism and thermogenesis disorders contribute to the hypermetabolic state of cancer cachexia in cachectic mice (5). Cancer cachexia can also cause wasting of the heart muscle, which is accompanied by cardiac remodeling and dysfunction (6). In addition to transporting inflammatory factors, blood also changes to a highly coagulable state (7). Changes in liver function might cause increased energy loss and mortality in patients with cancer cachexia, and these losses have been associated with changes in liver function and have been considered to account for a significant proportion of the energy loss in patients with cancer cachexia (8). Cachexia occurs in at least half of all patients with cancer (9).

In particular, patients with cancer are at a high risk of malnutrition because of the disease itself, and their treatments threaten their nutritional status (10). Disease-associated malnutrition is a common problem among patients with cancer, affecting 25–70% of patients with certain cancers (11). If untreated, malnutrition often progresses to severe wasting associated with cancer cachexia. The 10%–20% of cancer patients’ deaths can be attributed to malnutrition rather than to the malignancy itself (12). To diagnose cancer malnutrition, clinicians used body mass index (BMI), waist circumference, or triceps skin fold (TSF) (13). Recently, the Global Leadership
Initiative on Malnutrition (GLIM) provided a 2-step approach to the diagnosis of malnutrition based on phenotypic and etiologic criteria. The phenotypic criteria included weight loss, low BMI, and reduced muscle mass, and were assessed by physical examination, anthropometric measures, or assessments of muscle strength, such as hand grip strength (HGS). The etiologic criteria include inflammation and reduced food intake or assimilation\(^{14}\). Previous studies have also reported that a low skeletal muscle index (SMI) was associated with worse survival in patients with solid tumors\(^{15}\). However, SMI was based on the existing computed tomographic (CT) cross-sectional imaging and readily available software. We did not consider SMI as an anthropometric measure that would be easy to use for patients.

Although advances have been made in understanding the mechanisms of cachexia, translating these advances to the clinic has been challenging. We found that no relevant study has yet been conducted to determine which easily available measurement could predict the mortality of patients with cancer cachexia. Most patients with cancer face a huge financial burden, and many patients are forced to discontinue treatment because of financial problems. Reducing the financial burden is of great significance to patients with cancer in developing countries and poor families. Malnutrition and economic burden are most significant among patients with advanced cancer, especially in patients with cancer cachexia. Therefore, we aimed to find an anthropometric measure that was both economical and easily accessible for patients to understand the consumption of their body and predict survival in patients with cancer cachexia.

**Patients and Methods**

**Study population and design**

This was a retrospective analysis based on a multicenter clinical trial on cancer [Chinese Clinical Trial Registry (ChiCTR1800020329)]. A detailed description of the inclusion and exclusion criteria for the multicenter clinical trial project is provided in a previous report\(^{16}\). In summary, patients with cancer aged 18 years or older who were enrolled at 40 clinical centers throughout China were recruited from 2013 to
2020. This multicenter, large-scale, long-term follow-up prospective study aimed to help diagnose malnutrition in cancer patients in China, and to identify the related risk factors associated with negative outcomes. This study was approved by the medical ethical review committee of the registration hospital and was conducted in accordance with the Declaration of Helsinki.

**Patient characteristics**

Demographic data, including age, sex, height, weight, survival time, primary tumor site, TNM stage, chronic disease, family history of cancer, EORTC QLQ-30 (The European Organization for Research and Treatment of Cancer QLQ-C30), nutritional support, smoking status, alcohol consumption, tea consumption, total protein, creatinine, albumin, aspartate transaminase (AST), alanine transaminase (ALT), hemoglobin (Hb), neutrophils, lymphocytes, red blood corpuscles (RBCs), platelets (PLT), BMI, mid-arm circumference (MAC), TSF, HGS, and calf circumference (CC). All pathological stages were defined according to the 8th edition of the American Joint Committee on Cancer TNM staging system (17).

**Diagnosis of cancer cachexia**

Cancer cachexia was diagnosed according to the Fearon criteria: weight loss >5% over the past 6 months (in the absence of simple starvation); BMI <20 and any degree of weight loss >2%; or mid upper-arm muscle area (MAMA) by anthropometry (below the 5th percentile, men <23.25 cm², women <18.75 cm²), and any degree of weight loss >2% (18). MAMA was calculated using the following formula: MAMA (cm²) = (MAC (cm) -(3.14 × TSF (cm))² / (4×3.14).

**Assessment of variables**

All variables (physical assessment, anthropometric, laboratory, questionnaires) were performed within 48 hours after admission and analyzed before the start of any treatment. BMI was calculated using the following formula: BMI (kg/m²) = weight (kg) / height² (m²). MAC and TSF were measured at the dominant arm at the midpoint
between the acromion and olecranon. The CC was measured in the right leg with the participants lying in the supine position with 90° of knee flexion. The MAC and CC were measured using a plastic metric tape, and TSF was measured using a skinfold caliper. HGS was measured on the dominant hand using a Jamar dynamometer. The mid-arm muscle circumference (MAMC) was calculated using the following formula: MAMC (mm) = MAC (mm) - (3.14 × TSF (mm))^{19}. Lifestyle questionnaires were used to obtain information on smoking status, alcohol consumption, and tea consumption. EORTC QLQ-C30 was used to measure quality of life^{20}.

**Laboratory measurements**

Laboratory measurements included inflammatory and nutritional biomarkers. All blood tests were performed after at least 9 h of fasting within 24 h of hospitalization.

**Selection of case and control participants**

The current analysis used data from a nested case-control study design in which physical examination was measured in 266 patients who survived less than 1-year, as well as 266 manually matched controls. We chose one year as the limit because it is a standard time frame used in studies of other chronic medical conditions, such as congestive heart failure^{21}. Cases were selected from individuals with cancer cachexia who survived less than 1 year after being diagnosed in the hospital. Controls were selected from individuals with cancer cachexia who survived more than 1 year after diagnosis in the hospital, and controls were matched to cases by age (age ± 5 years), sex, tumor type, tumor stage, and hospital site. After excluding four pairs of cases and controls without physical examination, a total of 262 incident colorectal cancer cases and 262 matched controls with available baseline information were included in the analysis. After excluding 26 patients without TSF, 3084 patients were included in the test cohort.
Variable definitions

Age was grouped into young (≤65 years) and old (>65 years); albumin into low albumin (≤35 g/L) and high albumin (>35 g/L)\(^{(22)}\); neutrophils into high neutrophils (<6.30×10\(^9\)/L) and low neutrophils (≥6.30×10\(^9\)/L); RBC into low RBC (male<4.0×10\(^{12}\)/L, female<3.5×10\(^{12}\)/L), and normal RBC (male≥4.0×10\(^{12}\)/L, female≥3.5×10\(^{12}\)/L); BMI was grouped into underweight (≤18.5 kg/m\(^2\)), normal weight (18.5 - 25 kg/m\(^2\)), and overweight (>25 kg/m\(^2\))\(^{(23)}\). We categorized EORTC QLQ-C30 into low EORTC QLQ-C30 (≤55.5), high EORTC QLQ-C30 (>55.5), and TSF into low TSF (male <12.25 mm and female <12.05 mm), and high TSF (male≥12.25 mm and female ≥12.05 mm) by Youden index\(^{(24)}\).

Statistical analysis

Baseline characteristics are presented as the mean ± standard deviation (SD) for continuous variables, and as proportions for categorical variables. Differences in baseline characteristics between cases and controls were compared using the two-sample Wilcoxon rank-sum test or two-sample \(t\)-test for continuous variables and the \(\chi^2\) test for categorical variables. Odds ratios (ORs) and 95% confidence intervals (95% CIs) of cancer cachexia patients’ 1-year survival were estimated by modeling risk factors as continuous variables and modeling TSF in quartiles using conditional logistic regression, with and without adjustment for matched variables (EORTC QLQ-C30, albumin, neutrophils, RBC, chronic disease, family history of cancer). The matched variables were selected using stepwise regression. The cutoff values were based on the clinical standard\(^{(25)}\), WHO criteria\(^{(23)}\), or Youden index\(^{(26)}\). Heterogeneity across subgroups was assessed by fitting simultaneous logistic regressions, and the results are presented in forest plots. Interactions between subgroups and TSF were examined by likelihood ratio testing. Analyses in the base cohort (n=3084) were conducted using the Kaplan-Meier method and survival curves and time ROC.

For practical reasons, an increase in the AUC of 0.025 per additional risk factor...
is considered clinically relevant \cite{27}. A 2-tailed \( p < 0.05 \), was considered to be statistically significant in all analyses. All analyses were performed using R software, version 4.0.2.

**Results**

**Characteristics of patients**

Patients who survived less than 1 year tended to have higher EORTC QLQ-C30 scores (54.15±11.66 vs 49.60±8.60; \( p < 0.001 \)) higher neutrophil levels (5.79±3.71 vs 4.30±2.89; \( p < 0.001 \)), lower total protein (64.94±8.85 vs 67.51±7.40; \( p < 0.001 \)), lower albumin (35.30±5.49 vs 37.92±5.51; \( p < 0.001 \)), lower Hb (113.17±21.84 vs 120.27±18.11; \( p < 0.001 \)), lower BMI (20.17±2.92 vs 21.17±3.21; \( p < 0.001 \)), lower TSF (12.39±6.76 vs 14.68±7.30; \( p < 0.001 \)) and more nutritional support (45.4% vs 33.6%; \( p < 0.001 \)) at baseline than control subjects (\textit{Table 1}).

**Association between anthropometric measurements and 1-year survival of patients with cancer cachexia**

There was a significant positive association between TSF and 1-year survival of patients with cancer cachexia (adjusted \( p = 0.014 \); adjusted OR: 0.96; 95% CI: 0.93,0.99) (\textit{Table 2}, \textit{Fig 1}). When TSF was categorized into quartiles (Q1 <8 mm, Q2: 8–12 mm, Q3: 12–18 mm, Q4 ≥18 mm), TSF showed a stronger protective factor as it increased (\( p \) for trend = 0.067) (\textit{Supplementary Table 1}).

**Subgroup analyses**

Stratified analyses were performed to assess the association between TSF (as a continuous variable) and 1-year survival of patients with cancer cachexia in various subgroups. A significantly more positive association between TSF and 1-year survival was found in young patients (OR: 0.96; 95% CI: 0.93,0.99) than in older patients (OR: 0.94; 95% CI: 0.89, 0.99; \( P \)-interaction = 0.013). Similar results were observed in patients with chronic disease (OR: 0.97; 95% CI: 0.94,1.00) compared to patients without chronic disease (OR: 0.92; 95% CI: 0.87, 0.97; \( P \)-interaction = 0.049). Other
subgroups of different age, sex, quality of life, inflammatory, albumin, and treatments showed the same trend that the TSF was the protective factor (Fig 2, Supplementary Fig 2).

Analysis of total patients with cancer cachexia.

In the base cohort (n=3084), patients with high TSF had better survival probability \( p<0.001 \) (Fig3), with a median overall survival (OS) of 16.03 months, whereas patients with high TSF showed a median OS of 21.68 months. The AUC at 12 months of TSF, BMI, HGS, MAC, MAMC, and CC were 0.619, 0.424, 0.570, 0.561, 0.524, and 0.578. TSF had the highest AUC.

Compared with only TNM stage (AUC at 12 months=0.732, AUC at 24 months=0.764, AUC at 36 months=0.773) in predicting prognosis, the TNM stage and TSF showed the best improvement (AUC at 12 months=0.766, compared with 0.732, AUC increased>0.025 ) in predicting prognosis while the TNM stage and HGS (AUC at 12 months=0.752), the TNM stage and MAC (AUC at 12 months=0.746), the TNM stage and MAMC (AUC at 12 months=0.740), the TNM stage and CC (AUC at 12 months=0.752) were considered as not clinically relevant (compared with 0.732, AUC increased<0.025) (Fig4).

Discussion

Based on previous studies, we hypothesized that HGS, MAC, MAMC, CC, BMI, and TSF might be good anthropometric measurements that could predict cancer survival \(^{28,29}\). We wanted to find an anthropometric measurement for patients that were easily available at home and helped patients realize the consumption of their body. Based on our study, we found that TSF may be a good indicator for patients with malignant consumption and was sensitivity to the one-year survival of patients with cancer cachexia.

Reports have shown that the MAC (HR: 1.79; 95% CI: 1.48 to 2.16 in males and HR: 2.26; 95% CI: 1.71 to 3.00 in females) might be a more feasible and valid
Accepted manuscript

anthropometric measure of mortality than BMI (HR, 1.38, 95% CI, 1.17 to 1.61 in males and HR, 1.56, 95% CI, 1.10 to 2.21 in females) and CC (HR, 1.45, 95% CI, 1.22 to 1.71 in males and HR, 1.30, 95% CI, 1.15 to 1.48 in females) in elderly people. MAC and CC have been used to evaluate muscle mass, and da Silva et al. found that sarcopenia evaluated by MAC (HR, 1.57; 95% CI, 1.12 to 2.18) and CC (HR, 2.00; 95% CI, 1.45 to 2.76) showed a higher risk of mortality in a study conducted with 334 advanced cancer patients. We found that TSF and BMI, especially TSF, were associated with 1-year survival. The association between HGS, SMI, or CC and the 1-year survival of patients with cancer cachexia might be because the patients included in our study experienced severe malnutrition.

The obesity paradox is an interesting finding recently reported in patients with cancer; increased BMI is associated with an increased risk of common and less common malignancies, but in patients with cancer, overweight patients have longer survival times. These reports show that BMI is significantly associated with survival. Martin et al. reported that in patients with cancer cachexia, regardless of whether they presented as obese, the factors high weight loss, low muscle index, and low muscle attenuation were prognostic factors for survival [8.4 months (95% CI, 6.5 to 10.3) vs. 28.4 months (95% CI, 24.2 to 32.6), p < 0.001]. However, Sala et al. and Hurtado-López et al. found that arm anthropometry, such as MAC and TSF, is an alternative tool to identify malnutrition because arm anthropometry is not influenced by either large tumor masses or peripheral edema associated with the disease. This might explain why the TSF showed a better association with 1-year survival than BMI. We found the same positive association between TSF and survival in the baseline cohort (n = 3084). In a previous study, HGS was strongly associated with cancer mortality in cancer patients, but we found that TSF showed a much better associated with cancer mortalities. That might be because of the patients with cancer cachexia have been facing more serious malignant consumption of nutrition. TSF is a good index that could show the fat levels of patients, HGS shows the muscle function, MAMC is related to muscle mass, and other anthropometry indexes show...
the muscle and fat mass. In patients with cancer cachexia, the malignant consumption of nutrition might cause them to face the loss of both muscle mass and fat mass. In this study, we showed that the nutritional reserve represented by fat mass was sensitive to the one-year survival of patients with cancer cachexia, combined with the TNM stage. TSF increased the survival prediction performance of the TNM stage, but HGS and MAMC had no statistical association with 1-year survival in patients with cancer cachexia. The underlying causes may be that (1) lipolysis precedes skeletal muscle breakdown during the course of cancer cachexia\(^{(38)}\), and (2) adipose tissue loss is more sensitive than muscle mass loss in 1-year survival predicting.

Aging is often associated with malnutrition, and nutritional interventions have been used to delay aging and age-related diseases\(^{(39)}\). Assessing the nutritional status of the older population revealed an important significance in improving the lives of the elderly\(^{(40)}\). In the subgroup analyses, we observed the same results that the TSF was more sensitivity in the older population. Chronic diseases such as chronic kidney disease, cirrhosis, chronic liver disease, chronic pancreatitis, and diabetes always combine with a bad end\(^{(41-44)}\). We found that in patients without chronic disease, TSF might be a more sensitivity protective factor than in patients with chronic disease.

One strength of our study was that we excluded the influence of the hospital, tumor type and stage, age, and sex by building a nested case-control study. However, there are still some limitations that should be considered. First, because the study was retrospective, some anthropometric measurement data were not available, which may have resulted in selection bias. Second, the sample size of patients with cancer cachexia included in our study was very small, which may severely influence the findings of the subgroup analyses. Third, although we included many covariates in the regression models, the effects of unmeasured factors could not be excluded.

In conclusion, we found that the TSF might be a good anthropometric measurement for predicting 1-year survival in patients with cancer cachexia, especially in elderly patients or patients without chronic disease. Moreover, we found that TSF might be a more sensitivity malnutrition indicator than BMI or HGS in patients with cancer cachexia. We hope that doctors and patients will not only pay
attention to BMI but also consider TSF. Teaching patients to measure TSF regularly, such as once a month, could detect malnutrition and cachexia early, help patients take nutrition intervention timely, and improve clinical outcomes.

Acknowledgments

We would like to thank the data provider: Dr. Shi and all the authors who participated in this article for their contributions. Han-Ping Shi, Hong-Xia Xu, Chun-Hua Song, Chang Wang, Qi Zhang, Xi Zhang, Yi-Zhong Ge designed research; Kang-Ping Zhang, Meng Tang, Qi Zhang, Xi Zhang, Meng-Meng Song, Xiao-Wei Zhang, Ming Yang conducted research; Yi-Zhong Ge analyzed data; Yi-Zhong Ge and Guo-Tian Ruan wrote the paper; Yi-Zhong Ge had primary responsibility for final content. We would like to thank Editage (www.editage.cn) for English language editing.

Financial support

This work was supported by the National Key Research and Development Program (2017YFC1309200).

Conflicts of Interest

All authors read and approved the final manuscript.

Author Contributions

Han-Ping Shi, Hong-Xia Xu, Chun-Hua Song, and Chang Wang conceived and designed the work that led to the submission, acquired data, and/or played an important role in interpreting the results.

Yi-Zhong Ge, Guo-Tian Ruan, Meng Tang, and Xi Zhang drafted and revised the manuscript.

Yi-Zhong Ge, Qi Zhang, Han-Ping Shi, Meng-Meng Song, Xiao-Wei Zhang, Ming Yang, and Xian Shen approved the final version of the manuscript.

Yi-Zhong Ge and Kang-Ping Zhang agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
References


Figure Legends

Figure 1. The relation of TSF with 1-year survival of patients with cancer cachexia stratified.

Notes: The relation of TSH with 1-year survival of patients with cancer cachexia stratified unadjusted (A: as a continuous variable \( p < 0.001 \); OR: 0.95; 95% CI: 0.92, 0.97) and adjusted (B as a continuous variable \( p = 0.014 \); adjusted OR: 0.96; 95% CI: 0.93, 0.99). ORs of 1-year survival of patients with cancer cachexia and TSF were estimated by modeling TSF as a continuous variable using logistic regression analysis. Adjusted for EORTC QLQ-C30, albumin, neutrophils, RBC, chronic disease, family history of cancer. TSF, triceps skin fold; OR, odds ratio; CI, confidence interval; EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer QLQ-C30; RBC: red blood cell.
**Figure 2.** The association between TSF (as continue value) and the risk of 1-year survival of patients with cancer cachexia in various subgroups.

Notes: ORs of 1-year survival of patients with cancer cachexia relation to TSF (as continue value) were calculated using logistic regression models. Each subgroup analysis adjusted, if not stratified, for EORTC QLQ-C30, albumin, neutrophils, RBC, Chronic disease, family history of cancer. TSF, triceps skin fold; OR, odds ratio; CI, confidence interval; EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer QLQ-C30; RBC: red blood cell; BMI, body mass index.
Figure 3. Results of the Kaplan-Meier survival analysis for patients with cancer cachexia stratified by TSF.

Notes: Based on the patients with cancer cachexia follow up more than 1 year (n=3084). TSF, triceps skin fold; CI, confidence interval; HR, hazard ratio.
Figure 4. Comparing in improve the TNM stage in predicting prognosis.

Notes: Based on the patients with cancer cachexia follow up more than 1 year (n=3084). BMI, body mass index; TSF, triceps skin fold; HGS, handgrip strength; MAC: mid-arm circumference; MAMC, mid-arm muscle circumference; CC, calf circumference.
Supplementary Figure 1. Flow chart

Notes: A nested case-control study based on a multi-center clinical investigation.
**Supplementary Figure 2.** The association between TSF (as continue value) and the risk of 1-year survival of patients with cancer cachexia in different treatment subgroups.

Notes: ORs of 1-year survival of patients with cancer cachexia relation to TSF (as continue value) were calculated using logistic regression models. Each subgroup analysis adjusted, if not stratified, for EORTC QLQ-C30, albumin, neutrophils, RBC, chronic disease, family history of cancer. TSF, triceps skin fold; OR, odds ratio; CI, confidence interval; EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer QLQ-C30; RBC: red blood cell; BMI, body mass index.
Tables

**Table 1.** Detailed baseline characteristics of the study population

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>OS ≥ 1 year n=262</th>
<th>OS &lt; 1 year n=262</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic disease</td>
<td>93 (35.5)</td>
<td>84 (32.1)</td>
<td>0.460</td>
</tr>
<tr>
<td>Family history of cancer</td>
<td>39 (14.9)</td>
<td>43 (16.4)</td>
<td>0.718</td>
</tr>
<tr>
<td>EORTC QLQ-C30</td>
<td>49.60±8.60</td>
<td>54.15±11.66</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Nutritional support</td>
<td>88 (33.6)</td>
<td>119 (45.4)</td>
<td>0.007</td>
</tr>
<tr>
<td>Life style</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>129 (49.2)</td>
<td>137 (52.3)</td>
<td>0.541</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>63 (24.0)</td>
<td>78 (29.8)</td>
<td>0.168</td>
</tr>
<tr>
<td>Tea consumption</td>
<td>81 (30.9)</td>
<td>72 (27.5)</td>
<td>0.442</td>
</tr>
<tr>
<td>Laboratory measurements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Protein, g/L</td>
<td>67.51±7.40</td>
<td>64.94±8.85</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Creatinine, µmol/L</td>
<td>68.14±18.62</td>
<td>69.01±28.82</td>
<td>0.682</td>
</tr>
<tr>
<td>Albumin, g/L</td>
<td>37.92±5.51</td>
<td>35.30±5.49</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total bilirubin, µmol/L</td>
<td>12.60±8.64</td>
<td>17.18±30.96</td>
<td>0.021</td>
</tr>
<tr>
<td>AST, U/L</td>
<td>26.27±20.70</td>
<td>33.16±41.99</td>
<td>0.017</td>
</tr>
<tr>
<td>ALT, U/L</td>
<td>26.37±23.98</td>
<td>30.06±33.71</td>
<td>0.149</td>
</tr>
<tr>
<td>Hb, g/L</td>
<td>120.27±18.11</td>
<td>113.17±21.84</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Neutrophils, ×10^9/L</td>
<td>4.30±2.89</td>
<td>5.79±3.71</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lymphocyte, ×10^9/L</td>
<td>1.56±0.64</td>
<td>1.41±1.44</td>
<td>0.140</td>
</tr>
<tr>
<td>RBC, ×10^9/L</td>
<td>4.26±1.78</td>
<td>3.92±0.74</td>
<td>0.005</td>
</tr>
</tbody>
</table>
## Anthropometric measurements

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Mean ± SD Group 1</th>
<th>Mean ± SD Group 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLT, $\times 10^9$/L</td>
<td>236.21±95.46</td>
<td>258.88±117.91</td>
<td>0.016</td>
</tr>
<tr>
<td>MAC, cm</td>
<td>25.31±3.59</td>
<td>24.48±3.30</td>
<td>0.006</td>
</tr>
<tr>
<td>MAMC, cm</td>
<td>20.67±3.42</td>
<td>20.53±3.03</td>
<td>0.624</td>
</tr>
<tr>
<td>CC, cm</td>
<td>31.90±3.61</td>
<td>30.93±3.52</td>
<td>0.002</td>
</tr>
<tr>
<td>TSF Thickness, mm</td>
<td>14.68±7.30</td>
<td>12.39±6.76</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HGS, kg</td>
<td>24.15±8.53</td>
<td>22.10±9.77</td>
<td>0.011</td>
</tr>
<tr>
<td>BMI, kg/m$^2$</td>
<td>21.17±3.21</td>
<td>20.17±2.92</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

OS, overall survival; EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer QLQ-C30; AST: aspartate transaminase; ALT: alanine transaminase; Hb: hemoglobin; RBC: red blood cell; PLT: platelet; MAC: Mid-arm circumference; MAMC, mid-arm muscle circumference; CC, calf circumference; TSF Thickness, triceps skin fold thickness; HGS, handgrip strength; BMI, body mass index.

For continuous variables, values are mean ± SD; for categorical variables, values are n (%).

Differences in baseline characteristics were compared using $\chi^2$ test for categorical variables and two-sample t-test for continuous variables.
### Table 2. Result of conditional logistic regression analysis of anthropometric measurements and 1-year survival of patients with cancer cachexia

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Unadjusted</th>
<th>Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>TSF thickness, mm</td>
<td>0.95(0.92,0.97)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>0.90(0.85,0.95)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HGS, kg</td>
<td>0.96(0.94,0.99)</td>
<td>0.002</td>
</tr>
<tr>
<td>MAC, cm</td>
<td>0.93(0.88,0.98)</td>
<td>0.005</td>
</tr>
<tr>
<td>CC, cm</td>
<td>0.91(0.86,0.96)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

ORs of 1-year survival of patients with cancer cachexia relation to characteristics were calculated using conditional logistic regression models.

Each Characteristics analysis adjusted, if not stratified, for EORTC QLQ-C30, albumin, Neutrophils, RBC, Chronic disease, Family history of cancer.

OR, odds ratio; CI, confidence interval; TSF thickness, triceps skin fold thickness; BMI, body mass index; HGS, handgrip strength; MAC: Mid-arm circumference; CC, calf circumference; EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer QLQ-C30; RBC: red blood cell.
**Supplementary Table 1.** 1-year survival of patients with cancer cachexia associated with TSF concentration

| TSF (mm) | Cases/controls | Unadjusted | | Adjusted | |
| --- | --- | --- | --- | --- | |
| | | OR (95% CI) | P value | OR (95% CI) | P value |
| As continue value | | 0.945(0.917,0.973) | <0.001 | 0.962(0.931,0.994) | 0.019 |
| Quartiles | | | | | |
| <8 | 52/36 | ref. | ref. |
| 8-12 | 85/63 | 0.927(0.525,1.637) | 0.793 | 1.224(0.633,2.367) | 0.547 |
| 12-18 | 67/81 | 0.524(0.300,0.914) | 0.023 | 0.670(0.354,1.269) | 0.219 |
| ≥18 | 58/82 | 0.427(0.233,0.782) | 0.006 | 0.666(0.331,1.338) | 0.254 |
| P for trend | | <0.001 | 0.067 |

ORs of 1-year survival of patients with cancer cachexia were estimated by modeling TSF as a continuous variable and as quartiles using conditional logistic regression.

Each subgroup analysis adjusted, if not stratified, for EORTC QLQ-C30, albumin, Neutrophils, RBC, Chronic disease, Family history of cancer.

TSF, triceps skin fold; OR, odds ratio; CI, confidence interval; EORTC QLQ-C30, The European Organization for Research and Treatment of Cancer QLQ-C30; RBC: red blood cell.